CRL
Charles River LaboratoriesPrevious close
359.41
Change
−16.69 / −4.44%
P/E (TTM) ?
—
Market Cap
$17.0B
1M
+21.83%
S&P 500 −0.91% over same period
Volume / Avg Volume
1.5M / 1.4M
1.08× average
Latest earnings analysisFY2026 Q2Reported 2026-08-05
Charles River Q2 2026: $1.00 billion revenue, GAAP loss, guidance raised
Charles River posted $1.00 billion of second-quarter revenue and a small GAAP loss, but beat the $2.76 non-GAAP EPS consensus with $3.02 and raised full-year guidance. Read it as a transition quarter: divestitures and one-time charges distort the headline, while organic growth of 0.1% shows the core business is only starting to stabilise.
Read the full analysis →Revenue$1.00BYoY −2.70%
EPS (non-GAAP)$3.02Beatest. $2.76
Next-day move+1.84%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q2 Quarter ended 2026-06 | 2026-08-05 | $1.0B | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-05-07 | $996M | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-01-13 | $4.0B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-11-05 | $1.0B | Pending |
| FY2025 Q2 Quarter ended 2025-06 | 2025-08-06 | $1.0B | Pending |
| FY2025 Q1 Quarter ended 2025-03 | 2025-05-07 | $984M | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
A 5-year P/E range needs a longer earnings record; not yet comparable
Last 4 quarters: $324M in buybacks + $0 in dividends, 1.91% of market cap combined
P/E (TTM)
—
P/B
6.0
P/S
4.3
PEG
—
Earnings Reaction
Over the last 6 reports, the stock moved ±1.8% on average on the first trading day after, rising 3 times
Most recent +1.84%
Volatility & Correlation
1-year beta 1.31 · Correlation with S&P 500 0.36High beta
Annualized volatility 46% vs. 13% for the S&P 500
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 1 · $0.00MSell 12 · $35.2MNet selling $35.2M
- 10-22FOSTER JAMES CDirectorSell$8.4M24,042 shares · Avg price 350.00
- 10-21Parisotto Shannon MCEVP, Disc & Safety AssessmentSell$0.74M2,156 shares · Avg price 344.41
- 10-05Parisotto Shannon MCEVP, Disc & Safety AssessmentSell$0.30M981 shares · Avg price 308.44
- 09-30Coleman GlennEVP & Chief Financial OfficerBuy$0.00M10 shares · Avg price 297.43
- 08-25FOSTER JAMES CDirectorSell$10.1M33,561 shares · Avg price 300.00
- 08-19Parisotto Shannon MCEVP, Disc & Safety AssessmentSell$0.60M2,039 shares · Avg price 294.12
- 08-18Andrews Nancy CDirectorSell$0.16M573 shares · Avg price 285.24
- 08-11Parisotto Shannon MCEVP, Disc & Safety AssessmentSell$1.0M3,714 shares · Avg price 279.66
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q2 | 1.00 | −2.7% | — | -0.00 | -0.03 |
| FY2026 Q1 | 1.00 | +1.2% | — | -0.01 | -0.30 |
| FY2025 Q4 | 0.99 | −0.8% | — | -0.28 | -5.57 |
| FY2025 Q3 | 1.00 | −0.5% | — | 0.05 | 1.10 |
| FY2025 Q2 | 1.03 | +0.6% | — | 0.05 | 1.06 |
| FY2025 Q1 | 0.98 | −2.7% | — | 0.03 | 0.50 |
| FY2024 Q4 | 1.00 | −1.1% | — | -0.21 | -4.17 |
| FY2024 Q3 | 1.01 | −1.6% | 34.6% | 0.07 | 1.33 |
| FY2024 Q2 | 1.03 | −3.2% | 34.5% | 0.09 | 1.74 |
| FY2024 Q1 | 1.01 | −1.7% | 34.1% | 0.07 | 1.30 |
| FY2023 Q4 | 1.01 | −7.9% | — | 0.19 | 3.63 |
| FY2023 Q3 | 1.03 | +3.8% | 35.2% | 0.09 | 1.69 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| CRL | — | −2.7% | — | +21.83% | Neutral |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |